Keppra 750 mg film-coated tablets
*Company:
UCB (Pharma) Ireland LimitedStatus:
UpdatedLegal Category:
Product subject to medical prescription which may be renewed (B)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 18 October 2024
File name
ie-spc-fct-750mg-keppra.pdf
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 18 October 2024
File name
ie-pil-fct-keppra.pdf
Reasons for updating
- Change to section 4 - possible side effects
- Change to section 6 - marketing authorisation holder
Free text change information supplied by the pharmaceutical company
Type II: CCDS Update - Levetiracetam CCDS v8.0 – Cat B: Additional information regarding Drug Reaction with Eosinophilia and Systemic Symptoms, DRESS.
Updated on 01 March 2023
File name
Keppra 750 mg FCT.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 01 March 2023
File name
Keppra FCT PIL.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - possible side effects
Updated on 10 September 2021
File name
PIL FCT All.pdf
Reasons for updating
- Change to section 3 - how to take/use
- Change to section 4 - possible side effects
Free text change information supplied by the pharmaceutical company
Var II - CCDS.v.5.0 - Neuroleptic Malignant Syndrome
Updated on 10 September 2021
File name
SPC FCT 750 mg.pdf
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Var II - CCDS.v.5.0 - Neuroleptic Malignant Syndrome
Updated on 13 January 2021
File name
PIL FCT All.pdf
Reasons for updating
- Change to section 3 - how to take/use
Free text change information supplied by the pharmaceutical company
Update to recommend the same dosing for monotherapy and adjunctive therapy – SmPC Section 4.2 - PIL section 3
Updated on 13 January 2021
File name
SPC FCT 750 mg.pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Update to recommend the same dosing for monotherapy and adjunctive therapy – SmPC Section 4.2
Updated on 20 October 2020
File name
PIL FCT All.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Free text change information supplied by the pharmaceutical company
Addition of warning and adverse reaction of QT Prolongation – Section 2 & 4
Updated on 20 October 2020
File name
SPC FCT 750 mg.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Addition of warning and adverse reaction of QT Prolongation – Section 4.4 & 4.8
Updated on 31 July 2020
File name
spc 750 mg ie.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Addition of the warning and ADR on “Worsening Seizures”
Updated on 18 October 2019
File name
ie spc tabs 750 mg.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
In section 4.4 of the SPC the following has been added:
Abnormal and aggressive behaviours
Levetiracetam may cause psychotic symptoms and behavioural abnormalities including irritability and aggressiveness. Patients treated with levetiracetam should be monitored for developing psychiatric signs suggesting important mood and/or personality changes. If such behaviours are noticed, treatment adaptation or gradual discontinuation should be considered. If discontinuation is considered, please refer to section 4.2.
Updated on 18 October 2019
File name
ie pil tablets combined.pdf
Reasons for updating
- Change to section 4 - possible side effects
Free text change information supplied by the pharmaceutical company
In section 4 of the leaflet the following has been added:
Tell your doctor or pharmacist if any of the following side effects gets serious or last longer than a few days:
- Abnormal thoughts, feeling irritable or reacting more aggressively than usually, or if you or your family and friends notice important changes in mood or behaviour.
Updated on 01 April 2019
File name
20190328-ie-pil-fct-en-approved-current.pdf
Reasons for updating
- Change to section 4 - possible side effects
Updated on 29 March 2019
File name
20190328-ie-spc-tab-750mg-en-approved-current.pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.8 - Undesirable effects
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 13 March 2019
File name
20180426-ema-ie-pil-tabs-h277-en-approved-current.pdf
Reasons for updating
- Change to section 2 - pregnancy, breast feeding and fertility
- Change to section 3 - how to take/use
- Change to section 4 - possible side effects
Updated on 13 March 2019
File name
20180426-ema-ie-spc-tab-750mg-h277-en-approved-current.pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.8 - Undesirable effects
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Pregnancy wording update, dysgeusia, pregnancy malformation update and gait disturbance
Updated on 08 May 2017
Reasons for updating
- Change to section 6.3 - Shelf life
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 10 - Date of revision of the text
Free text change information supplied by the pharmaceutical company
- Section 6.3 Shelf Life (clarification / editorial / wording changes – actual shelf life not changed).
- Section 6.6 Special precautions for disposal and other handling (includes substantial changes to Instructions for reconstituting Actilyse).
- Section 10 (Revision date updated). The date of revision of the text has updated to align with the RMS approval dated 25Apr17.
Updated on 02 January 2017
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 23 December 2016
File name
PIL_15993_362.pdf
Reasons for updating
- New PIL for new product
Updated on 24 March 2015
Reasons for updating
- Change to section 1 - Name of medicinal product
- Change to section 2 - Qualitative and quantitative composition
- Change to section 3 - Pharmaceutical form
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.8 - Undesirable effects
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 4.9 - Overdose
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 6.1 - List of excipients
- Change to section 6.2 - Incompatibilities
- Change to section 6.3 - Shelf life
- Change to section 6.4 - Special precautions for storage
- Change to section 6.5 - Nature and contents of container
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 7 - Marketing authorisation holder
- Change to section 9 - Date of renewal of authorisation
- Change to section 10 - Date of revision of the text
Free text change information supplied by the pharmaceutical company
Further to receipt of renewal approval, the following are updated:
Sections 1, 2 and 7 (with minor typographical changes)
Sections 3 (re appearance), 4.2, 4.3, 4.4, 4.6, 4.8, 4.9, 5.1, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6 and 9 (with significant changes)
Section 10 (revision date updated from August 2013 to March 2015)
Updated on 01 November 2013
Reasons for updating
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 10 - Date of revision of the text
Free text change information supplied by the pharmaceutical company
Section 4.3 Contraindications
This section has been updated to include warnings for latex and gentamicin.
This section has been updated to include additional anticoagulation statements.
Section 4.4 Special Warnings and Precautions for Use
This section has been updated to include warnings for latex and gentamicin.
This section has been updated to include additional anticoagulation statements.
Section 6.6 Special Precautions for Disposal and Other Handling
The section header has been updated to now read Special precautions for disposal and other handling i.e. … of a used medicinal product or waste materials derived from such medicinal product and … of the product have been deleted.
Section 10 Date of Revision of the Text
The date has been updated from October 2011 to August 2013.
Updated on 16 April 2012
Reasons for updating
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.8 - Undesirable effects
- Change to section 4.9 - Overdose
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 10 - Date of revision of the text
Free text change information supplied by the pharmaceutical company
Section 4.1 Therapeutic Indications
The final paragraph (regarding fibrinolytic treatment of acute ischaemic stroke) has had text both added to and deleted from. The text … as early as possible …,
… 4.5 …, … after … and all that after … imaging techniques … is new.
Section 4.2 Posology and Method of Administration
The Acute ischaemic stroke sub-heading of this section has had both text added to and deleted from.
The text … only …, … under the responsibility and follow-up of …, … trained and experienced …, and … neurovascular … is new in the first paragraph.
The text … as early as possible …, … 4.5 … and the complete final sentence of the third paragraph is new.
Section 4.3 Contraindications
The second paragraph of this section has been added as new text.
The first bullet point of the Additional contraindications in acute ischaemic stroke sub-heading has been amended. The text … 4.5 …, … symptoms for which the …, … time … and … and could potentially be more than 4.5 hours ago (see section 5.1) has been added.
A new sub-heading entitled Use in elderly patients, together with corresponding text, has been added.
Section 4.4 Special Warnings and Precautions for Use
A new first paragraph has been added to this section.
The sub-heading Additional special warnings and precautions in acute ischaemic stroke has had both text added to and deleted from. The text … only …, … under the responsibility and follow-up of a … and … neurovascular … has been added.
A new third bullet point has been added to the Special warnings/conditions with a decreased benefit/risk ratio sub-heading.
A new penultimate paragraph (regarding data available from ECASS III) has been added to this section.
Section 4.5 Interaction with Other Medicinal Products and Other Forms of Interaction
The text … active substances which interfere with … has replaced the text … other agents inhibiting … in the second paragraph of this section.
Section 4.8 Undesirable Effects
The first paragraph of this section (regarding adverse reactions frequency and system organ class) has had text both added to and deleted from.
The text … and without any relevant increase in overall mortality and severe disability combined, i.e. mRS of 5 and 6 … has been added to the common category of the Haemorrhage sub-heading.
The text … ear haemorrhage … has been added to the uncommon category of the Haemorrhage sub-heading.
Section 4.9 Overdose
The text … severe bleeding results, the infusion of fresh frozen plasma or fresh blood is recommended and if necessary, synthetic antifibryinolytics may be administered … has been added to the first paragraph of this section.
Section 5.1 Pharmacodynamic Properties
The text … iv… and … s.c… has been replaced with the text … intravenous … and … subcutaneous … in the fourth paragraph of this section.
The Acute stroke sub-heading of this section has had both text added to and deleted from, including the addition of a new second paragraph regarding the ECASS III trial and the addition of a new third paragraph regarding the safety and efficacy of Actilyse for acute ischaemic stroke treatment.
Section 6.6 Special Precautions for Disposal and Other Handling
Minor editorial changes have been made to this section.
Section 10 Date of Revision of the Text
The date has been amended from November 2009 to October 2011.
Updated on 11 May 2010
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 6.3 - Shelf life
- Change to section 6.4 - Special precautions for storage
- Change to section 6.5 - Nature and contents of container
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 10 - Date of revision of the text
Free text change information supplied by the pharmaceutical company
Section 2 Qualitative and Quantitative Composition
The text Active ingredient: has been deleted as the first paragraph of this section.
Section 4.3 Contraindications
A new second paragraph for this section has been inserted i.e. paragraph commencing with the text: Additional contraindications in acute myocardial infarction, …
Section 4.4 Special Warnings and Precautions for Use
A new first paragraph for this section has been inserted i.e. paragraph commencing with the text: Special warnings and precautions in acute myocardial infarction, …
The word oedama has been corrected to spell oedema in the first sentence of the last paragraph of this section i.e. the one entitled Other special warnings.
Section 4.8 Undesirable Effects
The first paragraph of this section has been completely reworded i.e. the one regarding adverse reactions according to frequency and system organ class. Text has both been deleted from and added to this paragraph.
The word arrythmias has been corrected to spell arrhythmias in the very common paragraph of the Cardiac disorders heading of this section.
Section 5.1 Pharmacodynamic Properties
A new third paragraph has been added to this section i.e. one commencing with the text: Due to its relative fibrin-specificity alteplase at a dose of 100 mg leads to a modest decrease …
This paragraph was originally the first paragraph in section 5.2 (Pharmacokinetic Properties) and has moved location. No changes to the text itself have taken place.
Section 5.2 Pharmacokinetic Properties
What was originally the first paragraph of this section has been deleted and moved to section 5.1 (Pharmacodynamic Properties) where it has become the third paragraph of this section.
Section 6.3 Shelf-Life
The text 10 mg, 20 mg and 50 mg pack sizes has been added to now come before the text 3 years.
Section 6.4 Special Precautions for Storage
The text Do not store above 25ºC has been relocated to become the second sentence of the second paragraph of this section.
The text For 10 mg, 20 mg and 50 mg pack sizes: has been added as the first sentence of the second paragraph of this section.
Section 6.5 Nature and Contents of Container
The text For the 10 mg. 20 mg and 50 mg pack sizes, t has been added to and the capital T of the word the deleted from the beginning of the first sentence under the Solvent heading of this section.
The words injection and have been added to the first sentences of each strength pack size details in this section.
Section 6.6 Special Precautions for Disposal and Other Handling
A new fourth paragraph has been added to this section i.e. one commencing with the text When reconstituting the product from the respective amount of powder and solvent, …
Section 10 Date of Revision of the Text
The date March 2007 has been replaced with the date April 2010.
Updated on 06 February 2009
Reasons for updating
- Correction of spelling/typing errors
Updated on 07 December 2007
Reasons for updating
- Change to section 4.8 - Undesirable effects
Free text change information supplied by the pharmaceutical company
Updated on 02 August 2007
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.8 - Undesirable effects
- Change to section 5.3 - Preclinical safety data
- Change to section 6.3 - Shelf life
- Change to section 6.4 - Special precautions for storage
- Change to section 6.5 - Nature and contents of container
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 10 - Date of revision of the text
Free text change information supplied by the pharmaceutical company
Changes to section 4.2 - Posology and method of administration, Change to section 4.3 – Contraindications, Change to section 4.4 – Special warnings and special precautions for use, Change to section 4.5 – Interaction with other medicinal products and other forms of interaction, Change to section 4.8 – Undesirable effects.
Change details:
Section 4.2 Posology and method of administration.
The section on adjunctive therapy has been updated to incorporate current recommendations. It now states “Antithrombotic adjunctive therapy is recommended according to the current international guidelines for the management of patients with ST-elevation myocardial infarction”
Section 4.3 Contraindications
Acitylase is contraindicated in cases where there is a high risk of haemorrhage in a number of situations; this now includes patients with a “significant bleeding disorder at present or within the past 6 months”.
An additional contraindication for use in acute myocardial infarction and acute pulmonary embolism was any history of stroke. This has now been changed to include
“any known history of haemorrhagic stroke or stroke of unknown origin”
and “any known history of ischaemic stroke if transient ischaemic attack in the preceding 6 months, except current acute ischaemic stroke in the last 3 hours”.
Section 4.4 Special warnings and special precautions for use
This section now notes that the concomitant use of GPIIb/IIIa antagonists increases the risk of bleeding.
Section 4.5 Interaction with other medicinal products and other forms of interaction
This section now notes that the concomitant use of GPIIb/IIIa antagonists increases the risk of bleeding.
Section 4.8 – Undesirable effects
Corrections in the frequency classification of some undesirable effects. The following effects have been reclassified from uncommon to common:
Respiratory tract haemorrhage (such as pharyngeal haemorrhage, epistaxis, haemoptysis)
Gastrointestinal haemorrhage (such as gastric haemorrhage, gastric ulcer haemorrhage, haemorrhage rectum, haematemesis, melaena, mouth haemorrhage)
As with other thrombolytic agents some cardiac disorders have been reported as sequelae of myocardial infarction and / or thrombolytic treatment. Reperfusion arrythmias are now classified as a very common undesirable effect.
Gastrointestinal disorders: Nausea and vomiting have been reclassified from a rare to a common undesirable effect.
rare: fat embolism (cholesterol crystal embolisation), which may lead to corresponding consequences in the organs concerned
Updated on 14 February 2006
Reasons for updating
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 9 - Date of renewal of authorisation
- Change to section 10 - Date of revision of the text
Updated on 19 May 2005
Reasons for updating
- Correction of spelling/typing errors
Updated on 20 August 2003
Reasons for updating
- Improved electronic presentation
Updated on 25 June 2003
Reasons for updating
- New SPC for medicines.ie